Will medicinal cannabinoids prove to be useful clinically?

Current Drug Therapy

Volumn 2, Issue 2, 2007, Pages 143-150

  Smith, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoids; Cannabis; Multiple sclerosis; Pain; Spasticity

Indexed keywords

AJULEMIC ACID; CANNABIDIOL; CANNABINOID; CANNABINOID 2 RECEPTOR; CANNABINOL; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; LEVONANTRADOL; MEGESTROL; NABILONE; PLACEBO; RIMONABANT;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLODYNIA; AMNESIA; ANXIETY; ATTENTION DEFICIT DISORDER; BLURRED VISION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHORIA; ECG ABNORMALITY; FATIGUE; HERBAL MEDICINE; HUMAN; HYPERACTIVITY; HYPERALGESIA; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; MALIGNANT NEOPLASTIC DISEASE; MEMORY DISORDER; MULTIPLE SCLEROSIS; MUSCLE HYPOTONIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ORAL PARESTHESIA; PAIN ASSESSMENT; PHARYNX DISEASE; POSTOPERATIVE PAIN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPASTICITY; STRUCTURE ANALYSIS; TACHYCARDIA; URINARY DYSFUNCTION; WASTING SYNDROME; XEROSTOMIA;

EID: 34249321580     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488507780619059     Document Type: Review

References (73)

1. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-1270.
2. Smith PF. Evaluation of Sativex® (GW-1000). IDdb3 Current Drugs Database. http://www.iddb3.com 2004; 1-19.
3. ElSohly MA. Chemical constituents of Cannabis. In Grotenhermen F, Russo E (Eds), Cannabis And Cannabinoids, The Haworth Integrative Healing Press, New York, 2002; 27-36.
4. Smith PF. Sativex® (GW-1000). Curr Opin Investig Drugs 2004; 5: 748-754.
5. Piomelli D, Giuffrida A, Calignano A, et al. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-224.
6. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 2004; 68: 1691-1698.
7. Marsicano G, Goodneough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 65-67.
8. Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs 2001; 2: 399-414.
9. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
10. Kreitzer AC, Regehr WG. Retrograde signalling by endocannabinoids. Curr Opin Neurobiol 2002; 12: 324-330.
11. Alger BE. Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002; 68: 247-286.
12. Achiron A, Miron S, Lavie V, et al. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000; 102: 26-31.
13. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302.
14. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
15. Berrendero F, Sanchez A, Cabranes A, et al. Changes in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 2001; 41: 195-202.
16. British Medical Association. Therapeutic Uses Of Cannabis, Harwood Academic Publishers, Netherlands, 1997.
17. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48.
18. Hall WD, Degenhardt LJ, Currow D. Allowing the medical use of cannabis. Med J Aust 2001; 175: 39-40.
19. Smith PF. Cannabinoids for the treatment of multiple sclerosis: No smoke without fire? Exp Rev Neurotherapeutics 2003; 3: 327-357.
20. Smith PF. Medicinal cannabis extracts for the treatment of multiple sclerosis. Curr Opin Investig Drugs 2004; 5: 727-730.
21. Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids; in MS. Neurology 2002; 58: 1404-1407.
22. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526.
23. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-1669.
24. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
25. Fox P, Bain PG, Glickman S, et al. The effects of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62: 1105-1109.
26. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-441.
27. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-424.
28. Killestein J, Polman C. The therapeutic value of cannabinoids in MS: real or imaginary? Mult Scler 2004; 10: 339-340.
29. Shakespeare DT, Boggild, M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2000; 4: CD001332.
30. Campbell FA, Tramer MR, Carroll, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Brit Med J 2001; 323: 13-16.
31. Tramer MR, Carotl D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. Brit Med J 2001; 323:16-21.
32. Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect or oral delta-9-tetrahydrocannabinol (THC), morphine and a THC and morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-88.
33. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 N of l'studies. Anaesthesia 2004; 59: 440-452.
34. Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in post-operative pain. Pain 2003; 106: 169-172.
35. Karst M, Salim K, Burtsein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled study. JAMA 2003; 290: 1757-1762.
36. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112: 299-306.
37. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. Brit Med J 2004; 329: 253-261.
38. Attal N, Brasseur L, Guirimand D, et al. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004; 8: 173-177.
39. Rog DJ, Nurmikko TJ, Friede T, et el. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-819.
40. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50-52.
41. Holdcroft A, Maze M, Dore C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for post-operative pain management. Anesthesiology 2006; 104: 1040-1046.
42. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J Neurol 2006; 253(10): 1337-41.
43. Woolridge E, Barton S, Samuel J, et al. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 2005; 29: 358-367.
44. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004; 10: 425-433.
45. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central cancer treatment group study. J Clin Oncol 2002; 20: 567-573.
46. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
47. Despres JP, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
48. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006; 295: 761-775.
49. Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002; 30: 548-554.
50. Maas AIR, Murray G, Hennney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomized, placebo-controlled, clinical trial. Lancet Neurol 2005; 5:38-45.
51. Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901). J Cannabis Therap 2003; 3/4: 35-77.
52. Guy GW, Robson PJ. A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J Cannabis Therap 2003; 3/4: 79-120.
53. Guy GW, Flint ME. A phase I, double-blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Therap 2003; 3/4: 121-152.
54. Russo E. Cannabis and cannabis based medicine extracts: Additional results. J Cannabis Therap 2003; 3/4: 153-161.
55. Pope HG, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiat 2001; 58: 909-915.
56. Pope HG, Gruber AJ, Yurgelun-Todd D. Residual neuropsy-chological effects of cannabis. Curr Psych Rep 2001; 3: 507-512.
57. Fried P, Watkinson B, James D, et al. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ 2002; 166: 887-891.
58. Kelleher LM, Stough C, Serejew AA, et al. The effects of cannabis on information-processing speed. Addict Behav 2004; 29: 1213-1219.
59. Fergusson D, Poulton R, Smith PF, et al. Cannabis and psychosis. Brit Med J 2006; 332: 172-175.
60. Fried PA, Watksinson B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 2001; 23: 421-430.
61. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 2001; 23: 1-11.
62. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16 year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 2003; 25: 427-436.
63. Goldschmidt L, Richardson GA, Cornelius MD, et al. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol 2004; 26: 521-532.
64. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 2000; 22: 325-336.
65. Smith AM, Fried PA, Hogan MJ, et al. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol Teratol 2004; 26: 533-542.
66. McKallip RJ, Lombard C, Fisher M. et al. Delta-9-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Therap 2002; 302: 451-465.
67. El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 2004; 23: 149-156.
68. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection. Ann Intern Med 2003; 139: 258-266.
69. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following oral THC administration in humans. Psychopharmacology 1999; 141: 385-404.
70. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999; 141: 395-404.
71. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002; 97: 621-632.
72. Tanda G, Goldberg SR. Cannabinoids: reward, dependence and underlying neurochemical mechanisms - a review of recent pre-clinical data. Psychopharmacology 2003; 169: 115-134.
73. Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome associated anorexia. J Pain Symptom Manage 1997; 14: 7-14.